A New Medicine for Ischemic Stroke That Targets a Blood Clot Protein
A Novel Thrombolytic Targeting Von Willebrand Factor (VWF) to Treat Ischemic Stroke
This research is developing a new medicine to break up blood clots in patients experiencing an ischemic stroke, aiming for a safer and more effective treatment than current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11145271 on NIH RePORTER |
What this research studies
Currently, only one medicine is approved for acute ischemic stroke, but it can cause serious bleeding and often doesn't work well for larger clots. This project is creating a new type of clot-busting medicine that specifically targets a protein called Von Willebrand Factor (VWF), which is a key part of how stroke-causing clots form and grow. By focusing on VWF, researchers hope to develop a treatment that is both more effective at dissolving stubborn clots and safer, with fewer side effects like brain hemorrhage. This new approach could help more patients recover from stroke by quickly restoring blood flow to the brain.
Who could benefit from this research
Good fit: Future patients experiencing an acute ischemic stroke, especially those with large vessel occlusions or who cannot receive current treatments, would be ideal candidates for this potential therapy.
Not a fit: Patients who have already recovered from a stroke or those with hemorrhagic stroke would not directly benefit from this specific clot-dissolving treatment.
Why it matters
Potential benefit: If successful, this new medicine could offer a safer and more effective way to treat ischemic stroke, potentially reducing disability and saving lives.
How similar studies have performed: This approach is novel, building on preliminary data from stroke patients to develop a new thrombolytic agent, as current treatments have significant limitations.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Nimjee, Shahid — Ohio State University
- Study coordinator: Nimjee, Shahid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.